On September 17, 2020, the European Alliance for Access to Safe Medicines (EAASM) announced the availability of a report entitled Patient Safety and Nanomedicines: The need for a centralised regulatory procedure. According to EAASM, “[n]anomedicines and their follow-on products, also referred to as nanosimilars, are complex molecules and so regulatory oversight must be scientifically
nanomedicine
NIA Will Hold Webinar on Nanomedicine: Diagnostics and Therapeutics Advancing through Nanotechnology
By Lynn L. Bergeson & Carla N. Hutton on
Posted in International, Legal/Regulatory Issues
On March 7, 2018, the Nanotechnology Industries Association (NIA) will hold a webinar on “Nanomedicine: Diagnostics and therapeutics advancing through nanotechnology.” The webinar will focus on the diagnostic and therapeutic applications of nanotechnology, with the agenda including:
- Regulatory landscape in Europe and beyond for nanomaterials in healthcare applications; and
- Industry developments within
…